A practical reference on Phase 3 trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
== Pathology == The interosseous membranes of the leg and forearm also provide areas for muscle attachment. Damage to a syndesmotic joint, which usually results from a fracture of the bone with an accompanying tear of the interosseous membrane, will produce pain, loss of stability of the bones, and may damage the muscles attached to the interosseous membrane. If the fracture site is not properly immobilized with a cast or splint, contractile activity by these muscles can cause improper alignment of the broken bones during healing.
=== Environmental influence === It has been suggested that differences in penis size between individuals are caused not only by genetics, but also by environmental factors such as culture, diet and chemical or pollution exposure. Endocrine disruption resulting from chemical exposure has been linked to genital deformation in both sexes (among many other problems). Chemicals from both synthetic (e.g., pesticides, anti-bacterial triclosan, plasticizers for plastics) and natural (e.g., chemicals found in tea tree oil and lavender oil) sources have been linked to various degrees of endocrine disruption. Both PCBs and the plasticizer DEHP have been associated with smaller penis size. DEHP metabolites measured from the urine of pregnant women have been significantly associated with the decreased penis width, shorter anogenital distance and the incomplete descent of testicles of their newborn sons, replicating effects identified in animals. According to a 2008 study published by the US National Library of Medicine, approximately 25% of US women have phthalate levels similar to those observed in animals. Penile size may decrease as a result of some hormonal therapy combined with external beam radiation therapy. In addition, some estrogen-based fertility drugs like diethylstilbestrol (DES) have been linked to genital abnormalities or a smaller than normal penis (microphallus).
=== Estrogen excess === One of the main mechanisms for imbalance between estrogens and androgens is the overproduction of estrogens. A possible cause may be a neoplasm that originates from estrogen-secreting cells. Tumors that produce hCG stimulate production of estradiol while reducing other testicular hormone production. Obesity is another common cause of excess serum estrogens due to the presence of aromatase in peripheral tissue, which is a protein that converts androgens into estrogens. Peutz-Jeghers syndrome is a rare cause of testicular tumors that affect aromatase expression, which results in elevated serum estrogen levels. Aromatase excess syndrome is a rare genetic disorder that leads to increased conversion of androgens to estrogens in the body.
Exocrine glands secrete their products through a duct onto an outer or inner surface of the body, such as the skin or the gastrointestinal tract. Secretion is directly onto the apical surface. The glands in this group can be divided into three groups:
Sources: en.wikipedia.org
14 January During Operation Toan Thang II a convoy of the 48th Transportation Group was ambushed in Tây Ninh Province, 122 PAVN/VC were killed and three individual and one crew-served weapons were captured; U.S. losses were seven killed.
Functional metagenomics has enabled the discovery of several new antimicrobial resistance mechanisms and their related genes, one such example is the recently discovered tetracycline resistance mechanism by tetracycline destructases. It is important to incorporate not only the antimicrobial resistance gene sequence and mechanism but also the genomic context, host bacterial species and geographic location (metagenome).
The researcher will select a subset of the 'virtual library' for actual synthesis, based upon various calculations and criteria (see ADME, computational chemistry, and QSAR). In 1996, at Parke-Davis Pharmaceutical Research, scientist Anthony Czarnik directed research into and reported the first use of automation in synthesizing compound libraries. As the founding editor of the American Chemical Society's Journal of Combinatorial Chemistry, he also led research into RFID tags for targeted sorting in compound library synthesis.
Studies of Sue found a broken and healed fibula and tail vertebrae, scarred facial bones and a tooth from another Tyrannosaurus embedded in a neck vertebra, providing evidence for aggressive behavior. In 1992, William Abler suggested that Tyrannosaurus may have had infectious saliva used to kill its prey. Abler observed that the serrations (tiny protuberances) on the cutting edges of the teeth are closely spaced, enclosing little chambers, which he argued trapped pieces of carcass with bacteria, giving Tyrannosaurus a deadly, infectious bite, as the Komodo dragon was mistakenly thought to have. Jack Horner and Don Lessem, in a 1993 popular book, questioned Abler's hypothesis, arguing that Tyrannosaurus's tooth serrations as more like cubes in shape than the serrations on a Komodo monitor's teeth, which are rounded. The basis for an infectious bite in Tyrannosaurus was further undermined when it was found Komodo dragons do not actually have an infectious bite nor hunt by biting prey and tracking it as it weakens. Tyrannosaurus probably primarily processed carcasses with lateral shakes of the head, like crocodilians. The head was not as maneuverable as the skulls of allosauroids, due to flat joints of the neck vertebrae. Studies on hadrosaur vertebrae from the Hell Creek Formation that were punctured by the teeth of what appears to be a late-stage juvenile Tyrannosaurus indicate that despite lacking the bone-crushing adaptations of the adults, young individuals were still capable of using the same bone-puncturing feeding technique.
Dyspigmentation, the formation of wrinkles and other symptoms appear around regions of skin commonly exposed to the sun, mostly the eyes, mouth, and forehead. The lips may be affected. In Canadian women, the upper chest is commonly affected. Spider veins on face and neck Loss of color and fullness in the lips Symptoms of photoaging attributed to prolonged exposure to UV:
Sources: en.wikipedia.org
== References == Courtnall, Roy; Johnson, Chris (1999). The Art of Violin Making. London: Robert Hale. ISBN 0-7090-5876-4. Patrick Spielman. Gluing and Clamping: A Woodworker's Handbook. Sterling Publishing, 1986. ISBN 0-8069-6274-7 Weisshaar, Hans; Shipman, Margaret (1988). Violin Restoration. Los Angeles: Weisshaar~Shipman. ISBN 0-9621861-0-4.
== Production == The production methods for different isotopes vary, and only those for promethium-147 are given because it is the only isotope with industrial applications. Promethium-147 is produced in large quantities (compared to other isotopes) by bombarding uranium-235 with thermal neutrons. The output is relatively high, at 2.6% of the total product. Another way to produce promethium-147 is via neodymium-147, which decays to promethium-147 with a short half-life. Neodymium-147 can be obtained either by bombarding enriched neodymium-146 with thermal neutrons or by bombarding a uranium carbide target with energetic protons in a particle accelerator. Another method is to bombard uranium-238 with fast neutrons to cause fast fission, which, among multiple reaction products, creates promethium-147. As early as the 1960s, Oak Ridge National Laboratory could produce 650 grams of promethium per year and was the world's only large-volume synthesis facility. Gram-scale production of promethium was discontinued in the U.S. in the early 1980s, but will possibly be resumed after 2010 at the High Flux Isotope Reactor. In 2010, Russia was the only country producing promethium-147 on a relatively large scale.
== Toxicity == Phenformin sales began to decline in the U.S. from 1973 due to negative trial studies and reports of lactic acidosis. By October 1976, the U.S. Food and Drug Administration (FDA) Endocrinology and Metabolism Advisory Committee recommended phenformin be removed from the market. The FDA began formal proceedings in May 1977, leading to Phenformin's eventual withdrawal on November 15, 1978. In 1977, 385,000 patients with early-stage diabetes were taking phenformin in the U.S.. Ralph Nader's Health Research Group put the U.S. government under pressure to ban the drug. Ciba-Geigy Corp resisted, claiming there was no satisfactory alternative for many patients. But in July the FDA declared the drug an "imminent hazard to the public health" and gave doctors 90 days to switch to an alternative treatment (such as insulin, dietary restrictions or other drugs). As of 2008, phenformin was still legally available in Italy, Brazil, Uruguay, China, Poland, Greece and Portugal and cases of phenformin-induced lactic acidosis continued to be reported worldwide. In Hong Kong, where phenformin is banned, cases of phenformin-induced lactic acidosis occurred after taking Chinese proprietary medicines, claiming to be herbal, which were adulterated with phenformin. In the U.S., in 2001 the FDA recalled Chinese "herbal products" containing phenformin.
According to a 2009 leaked US Embassy cable, Houthis have reportedly established courts and prisons in areas they control. They impose their own laws on local residents, demand protection money, and dispense rough justice by ordering executions. AP's reporter, Ahmad al-Haj argued that the Houthis were winning hearts and minds by providing security in areas long neglected by the Yemeni government while limiting the arbitrary and abusive power of influential sheikhs. According to the Civic Democratic Foundation, Houthis help resolve conflicts between tribes and reduce the number of revenge killings in areas they control. The US ambassador believed that the reports that explain Houthi role as arbitrating local disputes were likely.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.